BLPH - Bellerophon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2018
12/31/2017
12/31/2016
Total Revenue
0
0
-
-
Operating Expenses
Research Development
11,010
20,259
17,854
16,650
Selling General and Administrative
6,832
7,621
6,745
7,107
Total Operating Expenses
17,842
27,880
24,599
23,757
Operating Income or Loss
-17,842
-27,880
-24,599
-23,757
Total Other Income/Expenses Net
5,506
24,877
-30,403
-590
Income Before Tax
-11,900
-2,625
-54,818
-24,252
Income Tax Expense
-1,801
-5,439
0
-438
Income from Continuing Operations
-10,099
2,814
-54,818
-23,814
Net Income
-10,099
2,814
-54,818
-23,814
Net Income available to common shareholders
-10,099
2,814
-54,818
-23,814
Basic EPS
-
0.75
-21.15
-23.70
Diluted EPS
-
-5.10
-21.15
-23.70
Basic Average Shares
-
3,830
2,597
1,004
Diluted Average Shares
-
4,337
2,597
1,004
EBITDA
-
-27,518
-24,226
-23,357